Article
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
The Lancet. Oncology - 1 Apr 2016
Cristofanilli Massimo, Turner Nicholas C, Bondarenko Igor, Ro Jungsil, Im Seock-Ah, Masuda Norikazu, Colleoni Marco, DeMichele Angela, Loi Sherene, Verma Sunil, Iwata Hiroji, Harbeck Nadia, Zhang Ke, Theall Kathy Puyana, Jiang Yuqiu, Bartlett Cynthia Huang, Koehler Maria, Slamon Dennis
Abstract excerpt
BACKGROUND: In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant improvements in progression-free survival compared with fulvestrant plus placebo in patients with metastatic breast cancer. Identification of patients most suitable for the addition of palbociclib to endocrine therapy after tumour recurrence is crucial for treatment...
Topics
Join the communities discussing this publication.